Center for Translational Research in Neurodegenerative Diseases

todd-goldeThe Center for Translational Research in Neurodegenerative Disease (CTRND) is a sister center to the CMDNR. The centers work in unison with one focusing on clinical and clinical research and the other on transaltional basic science. The CTRND has a state of the art, multi-disciplinary research center focused on the discovery, development and evaluation of future treatments and diagnostics for degenerative central nervous system conditions including PD, Alzheimer’s disease, Amyotrophic Lateral Sclerosis, Frontotemporal Lobar Degeneration, and Stroke. The yearly cost for PD and Alzheimer’s disease are estimated to be well over $500 billion per year and will likely reach several trillion dollars by 2050. Due to its large population and high percentage of elderly the impact of Alzheimer’s disease and PD in Florida is particularly large. This center enhances the understanding of the disease processes so that new therapies based on new discoveries can be developed. Discoveries in this center have created opportunities to develop novel preclinical models, explore fundamental mechanisms of disease, identify new therapeutic targets, and to ultimately develop and test novel therapies for PD, where in some cases there is little commercial or industry interest. Todd Golde, M.D. PhD. was recruited to the UF in late 2009 to build the CTRND. The center has tremendous intellectual capital, a diversity of faculty, a richness of resources, and an entrepreneurial spirit. The center has been translating basic discoveries in neurodegenerative disease into potentially more effective medical therapies. The goal of the center is to create a unique model that will not only support the best possible basic discovery programs but also the translation of those basic discoveries into tangible advances that benefit Alzheimer’s disease, PD and other neurodegenerative patients.  The center has 7 R01’s, 1 program project grant, and many foundation grants.